Ablation catheter maker sells for $170 million

St. Jude paid $170 million to acquire a Swiss company that specializes in force-sensing ablation catheters.

St. Jude announced that it is expanding its electrophysiology portfolio with the purchase of Endosense SA, a company in Geneva that developed a method using contact-force measurement in catheter ablation. St. Jude paid $170 million (159 million Swiss francs) and Endosense will receive up to an additional $161 million (150 million Swiss francs) if it achieves a regulatory milestone within a designated timeframe.  

Endosense’s TactiCath irrigated ablation catheter received CE mark in Europe for atrial fibrillation and supra ventricular tachycardia ablation, and has been studied in a trial in the U.S. under an investigational device exemption.

St. Paul-based St. Jude said it planned to submit a pre-market approval application with the FDA for paroxysmal atrial fibrillation by the end of the year.

Candace Stuart, Contributor

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Trimed Popup
Trimed Popup